MENOGARIL IN THE TREATMENT OF RELAPSED MULTIPLE-MYELOMA - A PHASE-II TRIAL OF THE CANCER CENTER OF WAKE-FOREST-UNIVERSITY

被引：1

作者：

CRUZ, JM ^{[1
]}

CASE, LD ^{[1
]}

DALTON, HB ^{[1
]}

RAMSEUR, WL ^{[1
]}

RICHARDS, F ^{[1
]}

JACKSON, DV ^{[1
]}

MUSS, HB ^{[1
]}

ZEKAN, PJ ^{[1
]}

BRODKIN, RA ^{[1
]}

BROWN, RC ^{[1
]}

HERRING, WB ^{[1
]}

LUSK, JA ^{[1
]}

OROURKE, MA ^{[1
]}

REDDY, SM ^{[1
]}

CAPIZZI, RL ^{[1
]}

机构：

[1] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103

来源：

INVESTIGATIONAL NEW DRUGS | 1992年 / 10卷 / 01期

关键词：

MENOGARIL; MULTIPLE MYELOMA;

D O I：

10.1007/BF01275478

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four of the 8 patients with stable disease had an improved performance status, and 3 had a decrease in analgesic use. The major toxicity was myelosuppression. The median progression-free interval was 3.0 months with a range of 0.7 to 22 months and median survival was 11.3 months with a range of 0.7 to 39 + months. Menogaril displays little activity in patients with previously treated MM.

引用

页码：35 / 37

页数：3

共 50 条

[21] Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia
Kucuk, O
Kilton, L
Wade, JL
Blough, R
Benson, AB
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (04): : 379 - 383
[22] PHASE-II STUDY OF RDNA HUMAN ALPHA-2 INTERFERON IN MULTIPLE-MYELOMA
WAGSTAFF, J
LOYNDS, P
SCARFFE, JH
CANCER TREATMENT REPORTS, 1985, 69 (05): : 495 - 498
[23] PHASE-II INVESTIGATION OF PENTOSTATIN IN MULTIPLE-MYELOMA - A SOUTHWEST-ONCOLOGY-GROUP-STUDY
GREVER, MR
CROWLEY, J
SALMON, S
MCGEE, R
KRAUT, EH
BUYS, SS
RIVKIN, SE
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (22) : 1778 - 1779
[24] PHASE-II STUDY OF RECOMBINANT ALPHA-2 INTERFERON IN RESISTANT MULTIPLE-MYELOMA
COSTANZI, JJ
COOPER, MR
SCARFFE, JH
OZER, H
GRUBBS, SS
FERRARESI, RW
POLLARD, RB
SPIEGEL, RJ
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (05) : 654 - 659
[25] Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
Farag, Sherif S.
Zhang, Shuhong
Jansak, Buffy S.
Wang, Xiaojing
Kraut, Eric
Chan, Kenneth
Dancey, Janet E.
Grever, Michael R.
LEUKEMIA RESEARCH, 2009, 33 (11) : 1475 - 1480
[26] PHASE-II STUDY OF SPIROGERMANIUM HYDROCHLORIDE WITH OR WITHOUT CYTOSINE-ARABINOSIDE IN THE TREATMENT OF ADVANCED RECURRENT LYMPHOMA AND MULTIPLE-MYELOMA
RIGGS, SA
CABANILLAS, F
ALEXANIAN, R
LEGHA, S
HAGEMEISTER, F
BARLOGIE, B
VELASQUEZ, W
MCLAUGHLIN, P
SALVADOR, P
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 184 - 184
[27] PHASE-II EVALUATION OF BISANTRENE IN REFRACTORY MULTIPLE-MYELOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY
DURIE, BGM
CROWLEY, J
COLTMAN, CA
CHAPMAN, RA
BALCERZK, SP
BONNET, JD
LIPSCHITZ, DA
STEPHENS, RL
CHESON, BD
INVESTIGATIONAL NEW DRUGS, 1991, 9 (04) : 329 - 331
[28] PHASE-II STUDY OF FLUDARABINE PHOSPHATE IN MULTIPLE-MYELOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY
KRAUT, EH
CROWLEY, JJ
GREVER, MR
KEPPEN, MD
BONNET, JD
HYNES, HE
SALMON, SE
INVESTIGATIONAL NEW DRUGS, 1990, 8 (02) : 199 - 200
[29] A PHASE-II TRIAL OF GOSERELIN (ZOLADEX) IN RELAPSED EPITHELIAL OVARIAN-CANCER
LIND, MJ
MILLWARD, MJ
CANTWELL, BMJ
CARMICHAEL, J
HARRIS, AL
BRITISH JOURNAL OF CANCER, 1990, 62 (03) : 518 - 518
[30] A PHASE-II TRIAL OF GOSERELIN (ZOLADEX) IN RELAPSED EPITHELIAL OVARIAN-CANCER
LIND, MJ
CANTWELL, BMJ
MILLWARD, MJ
ROBINSON, A
PROCTOR, M
SIMMONS, D
CARMICHAEL, J
HARRIS, AL
BRITISH JOURNAL OF CANCER, 1992, 65 (04) : 621 - 623

← 1 2 3 4 5 →